Literature DB >> 8101860

Cytokine mRNA expression during an in vitro response of human B lymphocytes: kinetics of B cell tumor necrosis factor alpha, interleukin (IL)6, IL-10, and transforming growth factor beta 1 mRNAs.

T Matthes1, C Werner-Favre, H Tang, X Zhang, V Kindler, R H Zubler.   

Abstract

Expression of mRNA for eight cytokines was analyzed in an in vitro response-proliferation and Ig-secretion--of normal human B lymphocytes. This was made possible by the use of murine thymoma cells as helper cells in conjunction with human T cell supernatant, and the design of human DNA sequence-specific primers for RT-polymerase chain reaction. mRNAs for interleukin (IL)2 and IL-4, but also for IL-1 alpha and IL-1 beta remained undetectable during the whole culture period in highly purified B cells prepared by a three-step purification protocol. However, tumor necrosis factor alpha and IL-6 mRNAs peaked during days 1-3 after culture start and became undetectable after 5-6 d, shortly before bulk B cell proliferation started to decline. In contrast, transforming growth factor beta 1 mRNA, after a progressive increase during the first few days, and IL-10 mRNA, after a peak on days 1-3, remained detectable in immunoglobulin (Ig)-secreting cultures throughout the observation period of 22 d. Clonal analysis on 8-d cultures that had been seeded with single B cells by autocloning with the cell sorter, revealed that 85% of 77 B cell clones studied, expressed TGF-beta 1 mRNA, and only 19% IL-10 mRNA. These findings show a differentiation stage-related cytokine program during a B cell response, whereby (a) B cells can become activated without IL-1 alpha or IL-1 beta expression; (b) mRNA for positive (IL-10) and negative (TGF-beta 1) autoregulatory factors coexists in cell populations during the later phase of the response, although not necessarily in all B cell clones; and (c) normal Ig-secreting cells cease IL-6 expression in contrast to their malignant counterparts, myeloma cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101860      PMCID: PMC2191113          DOI: 10.1084/jem.178.2.521

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  36 in total

1.  Cell surface antigen CD5 is a marker for activated human B cells.

Authors:  C Werner-Favre; T L Vischer; D Wohlwend; R H Zubler
Journal:  Eur J Immunol       Date:  1989-07       Impact factor: 5.532

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

4.  Human B cell lines can be triggered to secrete an interleukin 2-like molecule.

Authors:  D Benjamin; D P Hartmann; L S Bazar; R J Jacobson; M S Gilmore
Journal:  Cell Immunol       Date:  1989-06       Impact factor: 4.868

5.  Activation of normal human B cells through their antigen receptor induces membrane expression of IL-1 alpha and secretion of IL-1 beta.

Authors:  J Y Bonnefoy; M C Denoroy; O Guillot; C L Martens; J Banchereau
Journal:  J Immunol       Date:  1989-08-01       Impact factor: 5.422

Review 6.  Theoretical and practical aspects of B-cell activation: murine and human systems.

Authors:  R H Zubler; C Werner-Favre; L Wen; K Sekita; C Straub
Journal:  Immunol Rev       Date:  1987-10       Impact factor: 12.988

7.  Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells.

Authors:  Y Horii; A Muraguchi; S Suematsu; T Matsuda; K Yoshizaki; T Hirano; T Kishimoto
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

8.  Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies.

Authors:  F T Cordingley; A Bianchi; A V Hoffbrand; J E Reittie; H E Heslop; A Vyakarnam; M Turner; A Meager; M K Brenner
Journal:  Lancet       Date:  1988-04-30       Impact factor: 79.321

9.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

Authors:  M Kawano; T Hirano; T Matsuda; T Taga; Y Horii; K Iwato; H Asaoku; B Tang; O Tanabe; H Tanaka
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

10.  Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells.

Authors:  S S Sung; L K Jung; J A Walters; W Chen; C Y Wang; S M Fu
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

2.  Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression.

Authors:  N Kienzle; T B Sculley; L Poulsen; M Buck; S Cross; N Raab-Traub; R Khanna
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

3.  CD40 engagement triggers switching to IgA1 and IgA2 in human B cells through induction of endogenous TGF-beta: evidence for TGF-beta but not IL-10-dependent direct S mu-->S alpha and sequential S mu-->S gamma, S gamma-->S alpha DNA recombination.

Authors:  H Zan; A Cerutti; P Dramitinos; A Schaffer; P Casali
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

4.  Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cells.

Authors:  Johanna Rivera; Oscar Zaragoza; Arturo Casadevall
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts.

Authors:  Lucinda J Berglund; Danielle T Avery; Cindy S Ma; Leen Moens; Elissa K Deenick; Jacinta Bustamante; Stephanie Boisson-Dupuis; Melanie Wong; Stephen Adelstein; Peter D Arkwright; Rosa Bacchetta; Liliana Bezrodnik; Harjit Dadi; Chaim M Roifman; David A Fulcher; John B Ziegler; Joanne M Smart; Masao Kobayashi; Capucine Picard; Anne Durandy; Matthew C Cook; Jean-Laurent Casanova; Gulbu Uzel; Stuart G Tangye
Journal:  Blood       Date:  2013-10-24       Impact factor: 22.113

6.  CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line.

Authors:  A Cerutti; H Zan; A Schaffer; L Bergsagel; N Harindranath; E E Max; P Casali
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

7.  HIV-gp160 modulates differentially the production in vitro of IgG, IgA and cytokines by blood and tonsil B lymphocytes from HIV-negative individuals.

Authors:  F Cognasse; L Béniguel; R El Habib; O Sabido; P Chavarin; C Genin; O Garraud
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

8.  Regulation of cytokine expression by an autoreactive B cell clone derived from MRL/MP-lpr/lpr mice.

Authors:  T Iwasaki; T Hamano; J Fujimoto; A Ogata; E Kakishita
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

9.  Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10.

Authors:  I Roth; D B Corry; R M Locksley; J S Abrams; M J Litton; S J Fisher
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

10.  Comprehensive evaluation of 11 cytokines in premature infants with surgical necrotizing enterocolitis.

Authors:  Thomas Benkoe; Suzann Baumann; Manfred Weninger; Mario Pones; Carlos Reck; Winfried Rebhandl; Rudolf Oehler
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.